Dr Reddy's Laboratories shares were trading at Rs 2,594 apiece on the BSE in afternoon trade, down 1.60 per cent from its previous close.

Prabhudas Lilladher expects market to trade in the range of 5,600-6,000. Read to the top largecap stocks that can give good returns.

The market had reacted yesterday not to the top line growth of Ranbaxy. This is because that is very much in line with the expectations.

Ranbaxy's net loss for the December quarter would have been much more than Rs 2,982 crore which it has reported now.

Drug firm Ranbaxy Laboratories on Tuesday launched a generic version of Caduet, used for treating cardio vascular diseases, in the US marke...

Indian authorities have rejected the patent applications of GlaxoSmithkline’s anti-diabetic drug Avandia and Pfizer’s cholesterol lowering ...

Ranbaxy may shift production of the $1.5-billion drug Valacyclovir to its other FDA- approved facilities. The Top 10 food myths revealed | ...

Equities are seen lower Thursday tracking declines in the global markets. On the domestic front, higher inflation fears and political worri...

Ranbaxy has settled most of its patent disputes with Pfizer, allowing it to launch a generic version of Lipitor from November 30, 2011. Ran...

Pfizer has filed two separate patent infringement cases against Ranbaxy in a bid to extend the exclusivity of its $13-billion anti-choleste...

Ranbaxy has said the company will challenge the litigation filed by Pfizer, the world’s largest drug maker.